Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Takayuki Shimizu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2727-842X; OpenAlex author ID A5005900553. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 4 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 8

  1. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  2. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  3. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-021-04267-5↗
  4. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001826↗
  5. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.14925↗
  6. Clinical Predictors of Unresectable Disease at Laparotomy in Patients With Pancreatic Ductal Adenocarcinoma Planning to Undergo Surgical Resection. Co-author DOI 10.21873/anticanres.15335↗
  7. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/invivo.11700↗
  8. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection. Co-author DOI 10.1002/bjs.9775↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keiichi Kubota · 6 shared papers, 2015–2021 · strength 0.67
  2. Taku Aoki · 5 shared papers, 2019–2021 · strength 0.60
  3. Shozo Mori · 5 shared papers, 2019–2021 · strength 0.60
  4. Takatsugu Matsumoto · 4 shared papers, 2021 · strength 0.51
  5. Timothy R. Donahue · 2 shared papers, 2024–2026 · strength 0.39
  6. Zev A. Wainberg · 2 shared papers, 2024–2026 · strength 0.39
  7. Shimpei Maeda · 2 shared papers, 2024–2026 · strength 0.39
  8. Jason M. Link · 2 shared papers, 2024–2026 · strength 0.39
  9. Keith D. Lillemoe · 2 shared papers, 2024–2026 · strength 0.39
  10. William Reece Burns · 1 shared paper, 2026 · strength 0.23
  11. Theodore Sunki Hong · 1 shared paper, 2026 · strength 0.23
  12. Carlos Fernández-del Castillo · 1 shared paper, 2026 · strength 0.23
  13. Jin He · 1 shared paper, 2026 · strength 0.23
  14. Motaz Qadan · 1 shared paper, 2026 · strength 0.23
  15. Jonathan C. King · 1 shared paper, 2026 · strength 0.23
  16. Jennifer Yon-Li Wo · 1 shared paper, 2026 · strength 0.23
  17. Oscar Joe Hines · 1 shared paper, 2026 · strength 0.23
  18. Amol Kumar Narang · 1 shared paper, 2026 · strength 0.23
  19. Carlos F. Fernandez-del Castillo · 1 shared paper, 2024 · strength 0.17
  20. William R. Burns · 1 shared paper, 2024 · strength 0.17
  21. Joon Y. Park · 1 shared paper, 2024 · strength 0.17
  22. Mark D. Girgis MD · 1 shared paper, 2024 · strength 0.17
  23. Nikhil L. Chervu · 1 shared paper, 2024 · strength 0.17
  24. Jun Yu · 1 shared paper, 2024 · strength 0.17
  25. Christopher Lee Wolfgang · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.